Metformin Experience on Minimal Hepatic Encephalopathy

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary aim:

-To assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Secondary aim:

-To evaluate if metformin is a safety drug in patients showing liver cirrhosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Patients with > 18 years old

• Patients with the results of all the factors evaluable at the time of inclusion

• Patients who have accepted their participation in the study through informed consent

• Patients showing liver cirrhosis by ultrasound, transient elastography or liver biopsy

• Patients showing minimal hepatic encephalopathy (PHES < 4 or Critical Flicker Frequency < 39 Hz)

Exclusion Criteria:

• Patients with any contraindications to the drugs used

• Patients showing type 1 diabetes mellitus

• Patients showing type 2 diabetes mellitus and previous or current use of exogenous insulin, metformin or other oral antidiabetic drug